Alice Zwerling, PhD, MSc, BSc
Tel.: 613-562-5800 x8277
Dr Zwerling is an infectious disease epidemiologist with a special interest in tuberculosis (TB) and a focus on health economics. Her main areas of expertise and interest currently involve cost-effectiveness analyses to guide thoughtful implementation of new tools and treatment regimens for TB. Prior to joining the University of Ottawa, Dr Zwerling worked with the KNCV Tuberculosis Foundation in The Hague where she continues to provide technical support to national TB programs through the USAID funded Challenge TB program. Dr Zwerling has several ongoing International projects evaluating the cost-effectiveness of screening and active case finding programs for TB in the developing world. More recently, Dr Zwerling has begun working with the government of Nunavut and others to address key questions around cost-effectiveness of novel approaches and screening to address TB elimination across the Canadian arctic region and Canadian Inuit populations.
Infectious disease epidemiology, health economics, tuberculosis, global health, cost-effectiveness analysis, modelling, diagnostics, TB transmission, TB active case finding
1. Zwerling A, Dowdy D, von Delft A, Taylor H, Merritt MW. Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment. Int J Tuberc Lung Dis. 2017;21(11):69-74.
2. Zwerling A, Gomez GB, Pennington J, Cobelens F, Vassall A, Dowdy DW. A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens. Int J Tuberc Lung Dis. 2016;20(2):257-60.
3. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax. 2012;67(1):62-70.
4. Zwerling A, Cojocariu M, McIntosh F, Pietrangelo F, Behr MA, Schwartzman K, et al. TB screening in Canadian health care workers using interferon-gamma release assays. PLoS One. 2012;7(8):e43014.